- Home
- HIFS vs BCYC Comparison
HIFS vs BCYC Comparison
Compare HIFS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- BCYC
- Stock Information
- Founded
- HIFS 1834
- BCYC 2009
- Country
- HIFS United States
- BCYC United Kingdom
- Employees
- HIFS N/A
- BCYC N/A
- Industry
- HIFS Major Banks
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- HIFS Finance
- BCYC Health Care
- Exchange
- HIFS Nasdaq
- BCYC Nasdaq
- Market Cap
- HIFS 611.4M
- BCYC 566.5M
- IPO Year
- HIFS N/A
- BCYC 2019
- Fundamental
- Price
- HIFS $239.81
- BCYC $7.99
- Analyst Decision
- HIFS
- BCYC Buy
- Analyst Count
- HIFS 0
- BCYC 11
- Target Price
- HIFS N/A
- BCYC $25.00
- AVG Volume (30 Days)
- HIFS 54.4K
- BCYC 273.0K
- Earning Date
- HIFS 07-11-2025
- BCYC 08-12-2025
- Dividend Yield
- HIFS 1.06%
- BCYC N/A
- EPS Growth
- HIFS 63.41
- BCYC N/A
- EPS
- HIFS 15.35
- BCYC N/A
- Revenue
- HIFS $75,066,000.00
- BCYC $25,722,000.00
- Revenue This Year
- HIFS N/A
- BCYC $7.35
- Revenue Next Year
- HIFS N/A
- BCYC N/A
- P/E Ratio
- HIFS $15.95
- BCYC N/A
- Revenue Growth
- HIFS 37.00
- BCYC N/A
- 52 Week Low
- HIFS $209.71
- BCYC $6.10
- 52 Week High
- HIFS $300.00
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- HIFS 39.19
- BCYC 46.46
- Support Level
- HIFS $244.00
- BCYC $8.40
- Resistance Level
- HIFS $250.64
- BCYC $8.88
- Average True Range (ATR)
- HIFS 7.79
- BCYC 0.50
- MACD
- HIFS -2.47
- BCYC -0.00
- Stochastic Oscillator
- HIFS 10.28
- BCYC 24.40
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.